Commonwealth of Pennsylvania Public School Empls Retrmt SYS Grows Holdings in IDEXX Laboratories, Inc. $IDXX

Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,724 shares of the company’s stock after buying an additional 998 shares during the quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in IDEXX Laboratories were worth $10,579,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of IDXX. Bank of New York Mellon Corp boosted its holdings in IDEXX Laboratories by 156.2% in the second quarter. Bank of New York Mellon Corp now owns 1,451,390 shares of the company’s stock valued at $778,439,000 after purchasing an additional 884,808 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of IDEXX Laboratories by 71.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,988,912 shares of the company’s stock valued at $835,244,000 after purchasing an additional 825,965 shares in the last quarter. Generation Investment Management LLP acquired a new position in shares of IDEXX Laboratories in the 2nd quarter valued at approximately $304,277,000. Select Equity Group L.P. purchased a new position in shares of IDEXX Laboratories during the 1st quarter valued at approximately $194,834,000. Finally, Nuveen LLC acquired a new stake in shares of IDEXX Laboratories during the first quarter worth approximately $179,784,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently issued reports on IDXX. JPMorgan Chase & Co. upped their price target on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. UBS Group boosted their target price on shares of IDEXX Laboratories from $710.00 to $750.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 4th. Leerink Partners set a $785.00 price target on shares of IDEXX Laboratories in a research report on Monday, November 3rd. Weiss Ratings downgraded IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday. Finally, Stifel Nicolaus set a $775.00 price objective on IDEXX Laboratories in a report on Monday, November 3rd. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $730.50.

IDEXX Laboratories Stock Performance

Shares of IDXX opened at $689.93 on Monday. The firm has a fifty day moving average of $651.74 and a 200-day moving average of $589.87. The company has a market cap of $55.09 billion, a price-to-earnings ratio of 57.45, a price-to-earnings-growth ratio of 4.06 and a beta of 1.62. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $735.00.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, November 3rd. The company reported $3.22 earnings per share for the quarter, beating the consensus estimate of $3.14 by $0.08. The firm had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. IDEXX Laboratories’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same period last year, the firm posted $2.80 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. As a group, equities analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Insider Buying and Selling

In other news, Director M Anne Szostak sold 2,187 shares of the business’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the completion of the transaction, the director directly owned 262 shares in the company, valued at approximately $169,600.46. The trade was a 89.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Nimrata Hunt sold 9,425 shares of the stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the transaction, the executive vice president directly owned 21,149 shares of the company’s stock, valued at $14,874,937.66. This trade represents a 30.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.98% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.